Related Experiment Video
Updated: Jun 16, 2026
11:00
Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
Published on: September 18, 2017
Parvalbumin: Targeting calcium handling in cardiac diastolic dysfunction
Wang Wang1, Joshua Martindale, Joseph M Metzger
1Department of Integrative Biology and Physiology, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
General Physiology and Biophysics
|January 23, 2010
Summary
Parvalbumin (Parv) gene transfer improves diastolic heart failure by enhancing cardiac calcium handling. This approach targets defective myocardial relaxation and ventricular refilling, offering a promising therapy for diastolic dysfunction.
Area of Science:
- Cardiology
- Molecular Biology
- Biochemistry
Background:
- Diastolic heart failure (DHF) involves impaired myocardial relaxation and ventricular filling.
- Defective intracellular calcium (Ca2+) handling is a key mechanism in DHF.
- Developing targeted therapies for DHF is a significant clinical need.
Purpose of the Study:
- To investigate the therapeutic potential of Parvalbumin (Parv) gene transfer for diastolic heart failure.
- To evaluate Parv's role in modulating cardiac calcium handling and myocardial relaxation.
- To summarize existing research on Parv as a treatment for DHF.
Main Methods:
- Gene transfer of Parvalbumin (Parv) into cultured adult cardiac myocytes.
- In vivo studies assessing Parv's effects on diastolic function.
- Analysis of intracellular calcium (Ca2+) handling and sequestration in cardiac tissue.
Main Results:
- Parvalbumin facilitates myocardial relaxation by acting as a delayed calcium buffer.
- Gene transfer of Parv enhances calcium sequestration from the cytosol.
- Studies demonstrate Parv's efficacy in vitro and in vivo for improving diastolic function.
Conclusions:
- Parvalbumin gene transfer effectively addresses defective cardiac calcium handling in DHF.
- Parv shows significant promise as a therapeutic strategy for diastolic dysfunction.
- Targeting calcium handling proteins offers a novel approach to treating DHF.
Related Concept Videos
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...